Von Willebrand Disease Market

Market Overview:

The 7 major von Willebrand disease markets reached a value of US$ 537.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 918.3 Million by 2034, exhibiting a growth rate (CAGR) of 4.98% during 2024-2034.

The von Willebrand disease market has been comprehensively analyzed in IMARC's new report titled "Von Willebrand Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Von Willebrand disease refers to an inherited bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor (vWF), a protein involved in blood clotting. The indications of this ailment can vary widely depending on the severity of the condition. Some patients with mild forms may have few or no symptoms, while others may experience frequent nosebleeds, easy bruising, prolonged bleeding after injuries, blood in the urine and stool, heavy menstrual periods in females, etc. In rare cases, this illness also manifests as spontaneous bleeding into joints or internal organs. The diagnosis of von Willebrand disease involves a combination of clinical evaluation, medical history assessment, and laboratory tests to measure the levels and activity of vWF in the blood. A healthcare provider will further perform a physical examination to look for signs of bleeding or clotting abnormalities, such as bruises or tiny red spots on the skin. Additionally, several other diagnostic workups, like factor VIII assay, ristocetin cofactor assay, platelet function tests, etc., are utilized to confirm a diagnosis among patients.

The increasing cases of inherited genetic mutations that affect the production, structure, or function of vWF are primarily driving the von Willebrand disease market. In addition to this, the inflating utilization of certain blood-thinning drugs, such as aspirin, which can interfere with the normal clotting process and enhance the risk of bleeding tendencies among individuals, is also creating a positive outlook for the market. Moreover, the widespread adoption of desmopressin therapy, since it stimulates the release of vWF from the endothelial cells, thereby increasing its levels in the bloodstream and providing symptom relief in patients, is further bolstering the market growth. Apart from this, the escalating application of antifibrinolytic agents, including tranexamic acid and epsilon-aminocaproic acid, to prevent the breakdown of blood clots and reduce bleeding incidences is acting as another significant growth-inducing factor. Additionally, the emerging popularity of cryoprecipitate therapy for the treatment of the ailment on account of its several associated benefits, such as the quicker onset of action, improved availability, elevated compatibility, etc., is expected to drive the von Willebrand disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the von Willebrand disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for von Willebrand disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the von Willebrand disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the von Willebrand disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the von Willebrand disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current von Willebrand disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the von Willebrand disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the von Willebrand disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the von Willebrand disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of von Willebrand disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of von Willebrand disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of von Willebrand disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with von Willebrand disease across the seven major markets?
• What is the size of the von Willebrand disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of von Willebrand disease?
• What will be the growth rate of patients across the seven major markets?
   

Von Willebrand Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for von Willebrand disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the von Willebrand disease market?
• What are the key regulatory events related to the von Willebrand disease market?
• What is the structure of clinical trial landscape by status related to the von Willebrand disease market?
• What is the structure of clinical trial landscape by phase related to the von Willebrand disease market?
• What is the structure of clinical trial landscape by route of administration related to the von Willebrand disease market?